Existing drug opens new possibilities for treating child leukemia
Simple, familiar tactics can rein in the COVID variant
25 August 2021Exposure to tobacco smoke in early life is associated with accelerated biological ageing
25 August 2021Existing drug opens new possibilities for treating child leukemia
A new study from Linköping University has shown that the tumor-inhibiting gene TET2 is silenced in a large fraction of cases of acute lymphoblastic leukemia (ALL) in children. The scientists show that the gene can be reactivated by treatment with an existing drug, 5-azacytidine. The results, published in the scientific journal PNAS, suggest that 5-azacytidine may function as targeted therapy for ALL in children.
